Autolus Therapeutics (AUTL) AI Stock Analysis

• Market Cap: $399.21M
• Dividend Yield: N/A
• Average Volume (3M): 2.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.96
• Revenue Growth: 187.52%
• EPS Growth: 26.32%
• Country: US
• Employees: 647
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 266,141,420
• 10 Day Avg. Volume: 2,428,280
• 30 Day Avg. Volume: 2,523,908
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: 15.57
• Enterprise Value/Gross Profit: -23.14
• Enterprise Value/Ebitda: -1.97
• 1Y Price Target: $7.65
• Price Target Upside: 442.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 41 Neutral
• Price Target: $2.00 ▲(41.84% Upside)

Autolus Therapeutics faces significant financial challenges, with ongoing losses and negative cash flows weighing heavily on its stock score. While there are positive developments in product sales and regulatory approvals, these are overshadowed by high costs and market access issues. Technical indicators suggest bearish momentum, and the valuation remains unattractive due to negative earnings.

Positive Factors

Market Expansion

Aucatzyl is already gaining impressive market share early in its launch, differentiating itself versus competition.

Sales Performance

The continued impressive launch for Aucatzyl with $20.9 million in sales significantly beat estimates.

Negative Factors

Market Uncertainty

Aucatzyl is facing challenges in EU and UK with uncertainty around EU launch timing and potential impact from MFN.

Regulatory Delays

Autolus shares are down roughly 10% due to the delay and lack of clarity on timing for a potential EU launch for Aucatzyl.

Autolus Therapeutics Business Overview & Revenue Model

Company Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Autolus Therapeutics generates revenue through a combination of product development partnerships, licensing agreements, and potential future product sales. The company collaborates with larger pharmaceutical and biotechnology companies, leveraging their resources and expertise to advance its clinical programs. Key revenue streams include milestone payments from these partnerships upon achieving certain development stages, research funding, and potential royalties from product sales once therapies receive regulatory approval. Additionally, Autolus may benefit from government grants and collaborations aimed at accelerating the development of its innovative therapies.

Autolus Therapeutics Financial Statement Overview

Summary

Autolus Therapeutics is experiencing revenue growth but struggles with profitability and cash flow management. Despite a strong balance sheet with substantial cash reserves, ongoing operational losses and negative cash flows indicate weak financial health.

Income Statement

Autolus Therapeutics has shown significant revenue growth in recent years, with a notable increase from $1.7M in 2023 to $10.1M in 2024. However, the company continues to report negative gross and net profit margins, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting substantial operational losses.

Balance Sheet

The company's balance sheet highlights a strong equity position, with a substantial cash reserve relative to its liabilities. The debt-to-equity ratio is low at 0.12, suggesting limited leverage, but the company has consistently negative net income affecting ROE, which remains negative. The equity ratio is relatively stable, indicating a solid asset structure.

Cash Flow

Autolus Therapeutics is facing challenges with negative free cash flow, which has worsened in recent periods. Although operating cash flow is negative, it is supported by financing activities, indicating reliance on external funding. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.93M	10.12M	1.70M	6.19M	2.33M	242.00K
Gross Profit	-20.15M	-1.27M	-4.87M	-131.03M	-126.32M	-134.65M
EBITDA	-236.77M	-233.07M	-156.77M	-135.54M	-132.01M	-160.51M
Net Income	-227.78M	-220.66M	-208.38M	-148.84M	-142.10M	-142.09M
Balance Sheet
Total Assets	720.98M	782.73M	375.38M	490.27M	405.56M	294.24M
Cash, Cash Equivalents and Short-Term Investments	454.28M	588.02M	239.57M	382.44M	310.34M	153.30M
Total Debt	64.53M	297.23M	52.97M	24.26M	21.00M	54.16M
Total Liabilities	374.52M	355.40M	263.91M	191.60M	92.24M	84.20M
Stockholders Equity	346.46M	427.32M	111.47M	298.67M	313.32M	210.03M
Cash Flow
Free Cash Flow	-311.99M	-241.09M	-156.57M	-123.15M	-126.72M	-132.44M
Operating Cash Flow	-263.02M	-206.27M	-145.59M	-112.31M	-117.86M	-117.76M
Investing Cash Flow	-356.81M	-394.55M	-10.99M	-10.84M	-8.86M	-14.68M
Financing Cash Flow	29.42M	589.55M	-883.00K	223.61M	284.06M	74.42M

Autolus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Negative. The current price of 1.41 is below the 20-day moving average (MA) of 1.88, below the 50-day MA of 2.20, and below the 200-day MA of 2.08, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 23.20 is Positive, neither overbought nor oversold. The STOCH value of 6.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AUTL.

Autolus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
ALT	51 Neutral	$338.03M	―	-55.91%	―	-95.11%	27.25%
ABSI	46 Neutral	$357.36M	―	-57.39%	―	27.32%	-1.34%
TRML	45 Neutral	$601.20M	―	-29.62%	―	―	6.66%
RAPP	44 Neutral	$643.46M	―	-29.42%	―	―	―
CELC	44 Neutral	$2.17B	―	-134.54%	―	―	-25.61%
AUTL	41 Neutral	$399.21M	―	-52.18%	―	187.52%	26.32%

Autolus Therapeutics Corporate Events

Autolus Reports Q2 2025 Financial Results

Autolus Therapeutics reported its financial results for Q2 2025, highlighting a net product revenue of $20.9 million from AUCATZYL®, which recently received conditional marketing authorization in the UK and EU. The company is advancing its clinical trials, with plans to initiate a Phase 2 trial in lupus nephritis and a Phase 1 trial in multiple sclerosis by the end of 2025. Despite a net loss of $47.9 million for the quarter, Autolus remains optimistic about its cash position and future growth opportunities, particularly with the promising data from the FELIX trial and the potential of obe-cel in treating autoimmune diseases.

Autolus Therapeutics Passes All AGM Resolutions

On June 26, 2025, Autolus Therapeutics held its Annual General Meeting where all nine proposed resolutions were passed. Key resolutions included the adoption of the 2024 Annual Report, approval of the Directors’ remuneration report and policy, re-appointment of Ernst & Young LLP as auditors, re-election of Dr. R Iannone and Dr. R Rao as Directors, and the approval of the Employee Share Purchase Plan.